StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Salazosulfapyridin

Sulfasalazine

HCID 5339
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
599-79-1
Standard-SMILES
O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
InChIKey
NCEXYHBECQHGNR-UHFFFAOYSA-N
Summenformel
C18H14N4O5S
Durchschnittliche Molmasse
398,4 g/mol
Monoisotopische Masse
398,06849055

Überblick

Sulfasalazine (salicylazosulfapyridine) can cause cancer according to The National Toxicology Program. It can cause male reproductive toxicity according to state or federal government labeling requirements.

Namen und Bezeichner

Bevorzugter Name
Sulfasalazine
IUPAC
2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid
Lokaler Name
Salazosulfapyridin
Englischer Name
Sulfasalazine
Summenformel
C18H14N4O5S
Molmasse
398.39

Namen und Synonyme

sulfasalazine599-79-1SalicylazosulfapyridineSulphasalazineAzulfidineSalazosulfapyridineSalazopyrinBenzosulfaSulcolonSalazopyridinAsulfidineAzopyrine
Weitere Namen anzeigen
saspsulfasalazinSSZs.a.s.-500si-88
AccucolAzopyrinSalisulfSalazopiridazinReupirinw-t Sasp oralColo-PleonSalazosulfapyridin

Datenbank-Bezeichner

CAS
599-79-1
PubChem CID
5339
DTXSID
DTXSID0021256
ChEMBL
CHEMBL100848、CHEMBL242373
ChEBI
CHEBI:9334
UNII
3XC8GUZ6CB
Nikkaji
J2.073G

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-0,7
Polarare Oberfläche (TPSA)
150 Ų
H-Brücken-Donoren
3
H-Brücken-Akzeptoren
9
Frei drehbare Bindungen
6
Schwere Atome
28
Formalladung
0
Komplexität
657

Experimentelle und physikochemische Eigenschaften

Drugs · 4 Einträge

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Antibiotics

Pharmaceuticals -> Analgesics and anti-inflammatories

Pharmaceuticals -> Listed in ZINC15

LogP-0.13
SolubilityPractically insoluble in water
Dissociation Constants · 2 Einträge

2.65

0.6

Collision Cross Section · 4 Einträge

203.9 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID0021256]

199.36 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

200.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

199.7 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physikochemische Eigenschaften

Schmelzpunkt
260 · 260-265 °C (dec.)(lit.)
Siedepunkt
689.3 · 689.3±65.0 °C(Predicted)
Dichte
1.3742 · 1.3742 (rough estimate)
Brechungsindex
1.6 · 1.6000 (estimate)
storage temp.
Keep in dark place,Sealed in dry,Room Temperature
Löslichkeit
4 OH · NH4OH 1 M: 50 mg/mL, clear, red
pka
0.6 · pKa 0.6(H2O t = 20 I < 0.001) (Uncertain);2.4(H2O t = 20 I < 0.001) (Uncertain);9.7(H2O t = 20 I < 0.001) (Uncertain);11.8(H2O t = 20 I < 0.001) (Uncertain)
Aggregatzustand
powder
Farbe
Orange
Wasserlöslichkeit
0.1 g/100 · <0.1 g/100 mL at 25 ºC
Merck
14 · 14,8942
BRN
356241 · 356241
BCS Class
2 · 2,4
Stabilität
1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.
Major Application
forensics and toxicologypharmaceutical (small molecule)
InChI
1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+
InChIKey
NCEXYHBECQHGNR-QZQOTICOSA-N
SMILES
OC(=O)c1cc(ccc1O)\N=N\c2ccc(cc2)S(=O)(=O)Nc3ccccn3
CAS Datenbank
599 · 599-79-1(CAS DataBase Reference)
EPA chemische Informationen
Salicylazosulfapyridine (599-79-1)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

EPA Human Health Benchmarks for Pharmaceuticals · 6 Einträge

Sulfasalazine

46.6

197.2

Maintenance therapy dosage for adults is 2 g daily.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 2000 mg/day, Lowest Therapeutic Dose (LTD): 25.0 mg/kg-day, and Screening Dose: 0.008 mg/kg-day.

10-Feb-21

Sicherheitsdaten

F
8
wgk
2
ridadr
3077
hs_code
2933399090
RTECS-Nr.
VO6250000
risk_code
42/43
Toxizität
LD50 oral in rabbit: > 7500mg/kg
hazard_code
Xn
safety_code
22-29/56-45
Speicherklasse
11 - Combustible Solids
Giftige Stoffe Daten
599-79-1(Hazardous Substances Data)
Hazard Classifications
Aquatic Chronic 2Carc. 2Repr. 2Resp. Sens. 1Skin Sens. 1

Chemie und Industrie

Pharmakologische Informationen

ATC CodeA07EC01
Protein BindingSulfasalazine is highly bound to albumin (>99.3%) while sulfapyridine is only about 70% bound to albumin. Acetylsulfapyridine, the principal metabolite of sulfapyridine, is approximately 90% bound to plasma proteins.
Pharmacodynamics · 1 Eintrag

The mode of action of sulfasalazine or its metabolites, 5-aminosalicylic acid and sulfapyridine, is still under investigation but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and <i>in vitro</i> models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver, and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of sulfasalazine, sulfapyridine, and 5-aminosalicylic acid have indicated that the major therapeutic action may reside in the 5-aminosalicylic acid moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown.

Mechanism of Action · 1 Eintrag

Although the exact mechanism of action of sulfasalazine is not fully understood, it is thought to be mediated through the inhibition of various inflammatory molecules. Research have found that sulfasalazine and its metabolites, mesalazine and sulfapyridine, can inhibit leukotrienes and prostaglandins by blocking the cyclo-oxygenase and lipoxygenase pathway. Specific enzymes that were investigated include phospholipase A2, cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX2), and arachidonate 5-lipoxygenase. Inhibitory activities on other non-arachidonic acid derivatives have also been observed, including PPAR gamma, NF-Kb, and IkappaB kinases alpha and beta.

Biological Half-Life · 1 Eintrag

The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.In fast acetylators, the mean plasma half-life of sulfapyridine is 10.4 hours while in slow acetylators, it is 14.8 hours.Due to low plasma levels produced by 5-aminosalicylic acid after oral administration, reliable estimates of plasma half-life are not possible.

Metabolism/Metabolites · 1 Eintrag

In the intestine, sulfasalazine is metabolized by intestinal bacteria to sulfapyridine and 5-aminosalicylic acid. Of the two species, sulfapyridine is relatively well absorbed from the intestine and highly metabolized, while 5-aminosalicylic acid is much less well absorbed.Approximately 15% of a dose of sulfasalazine is absorbed as the parent drug and is metabolized to some extent in the liver to the same two species.Sulfapyridine can also be metabolized to 5-hydroxysulfapyridine and N-acetyl-5-hydroxy sulfapyridine. 5-aminosalicylic acid is primarily metabolized in both the liver and intestine to N-acetyl-5 aminosalicylic acid via a non-acetylation phenotype-dependent route.

Absorption, Distribution and Excretion · 4 Einträge

Following oral administration of 1 g of sulfasalazine to 9 healthy males, less than 15% of a dose of sulfasalazine is absorbed as the parent drug. Detectable serum concentrations of sulfasalazine have been found in healthy subjects within 90 minutes after ingestion. Maximum concentrations of sulfasalazine occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 μg/mL) occurring at 6 hours.

Absorbed sulfapyridine and 5-aminosalicylic acid and their metabolites are primarily eliminated in the urine either as free metabolites or as glucuronide conjugates. The majority of 5-ASA stays within the colonic lumen and is excreted as 5-aminosalicylic acid and acetyl-5-aminosalicylic acid in the feces.

Following intravenous injection, the calculated volume of distribution for sulfasalazine was 7.5 ± 1.6 L.

The calculated clearance of sulfasalazine following intravenous administration was 1 L/hr. Renal clearance was estimated to account for 37% of total clearance.

Anwendungen · 2 Einträge

BeschreibungSulfasalazine (brand name Azulfidine in the U.S., Salazopyrin and Sulazine in Europe and Hong Kong) was developed in the 1950s specifically to treat rheumatoid arthritis. It was believed at the time that bacterial infections were the cause of rheumatoid arthritis. Sulfasalazine is a sulfa drug, (a derivative of mesalazine) and is formed by combining sulfa pyridine and salicylate with an azo bond. It may be abbreviated SSZ.

VerwendenSulfasalazine is an anti-inflammatory (gastrointestinal). Sulfasalazine has been used in granulomatous colitis.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

BenzolsulfonsäurechloridEssigsure2-PyridylaminSulfapyridinAcetanilid5-Aminosalicylsure4-Nitroso-N-2-pyridinylbenzenesulfonamideSalicylsäureN-AcetylsulfanilylchloridNatriumhydroxid

Ergänzende Hinweise

DefinitionChEBI: An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Zugehörige Reaktionen

4
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1750338
HRID 1750338als Edukt
Reaktionsgleichung von HRID 2202207
HRID 2202207als Edukt
Reaktionsgleichung von HRID 2205960
HRID 2205960als Edukt
Reaktionsgleichung von HRID 2272552
HRID 2272552als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung